Article
Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States.
Lawrenceville, NJ — Aton Pharma has launched new education, distribution, sampling, and reimbursement programs for its preservative-free formulation of timolol maleate (Timoptic in Ocudose), which according to the company is the only preservative-free medication for glaucoma available in the United States.
Aton acquired the U.S. marketing rights to the product line from Merck & Co. in February. The non-selective beta-adrenergic receptor blocking agent is indicated for the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma.
The company said it plans to support the drug with advertising in ophthalmic publications, a coupon program, direct mail promotion, and a patient information Web site, www.ocudose.com . Its sales force will re-introduce the timolol formulation to eye-care professionals.
“We will concentrate on enhancing distribution, sampling, and reimbursement assistance while increasing patient and provider awareness,” said Michael G. Wells, chief executive officer of Aton. “With [this formulation of timolol], we are able [to] serve yet another niche market that is greatly underserved: glaucoma patients who will benefit from preservative-free medications.”
William Trattler, MD, director of cornea at the Center of Excellence in Eyecare in Miami, said, “A preservative-free beta blocker is a consideration for many glaucoma patients, who must use medication frequently and for long periods of time. This is a particular concern for those who already have dry eye or are at increased risk for ocular surface disease, such as the elderly, those [taking] oral medications associated with dry eye, and patients with existing lid margin disease.”
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.